Our study demonstrates that elevated SM promotes ocular surface inflammation and cellular injury. Inhibition of SM synthase by Ly93 alleviates DED-associated inflammation and injury, suggesting that targeting SM metabolism represents a promising therapeutic strategy.
Chen et al. (2026) studied this question.